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ABSTRACT
Objectives. Evaluate the effects of a 6-month High Intensity Interval Training (HIIT) program on (1) func-
tional capacity and health-related quality of life, (2) multiple blood biomarkers, (3) echocardiographic
parameters, and (4) exercise performance, in patients in cardiac resynchronization therapy (CRT) strati-
fied by the presence of atrial fibrillation (AF), targeting the following questions: (1) Does CRT provide
similar benefits in patients in AF and sinus rhythm (SR)?; and (2) Does HIIT provides similar benefits in
patients in AF and SR? Design. Estimates were available at baseline and 6 months after CRT implant-
ation in 37 patients with heart failure. Patients were randomized after CRT to a 24-week HIIT group or
to a usual care group (CON). In this sub-analysis, HIIT (AF ¼ 7; SR ¼ 11) and CON (AF ¼ 9; SR ¼ 10)
were stratified by the presence of AF. Results. Patients in AF benefitted to a lesser degree from CRT in
functional status than patients in SR (23.8–46.0%). However, HIIT induced superior improvements in
patients in AF compared to CON (23.9–61.0%). Decreases in TNF-a (8.5–42.9%), BNP (15.3–34.6%) and
left ventricular mass (9.6–26.2%) were only observed in patients in SR, whereas increases in peak oxy-
gen uptake were only observed in patients in AF (19.5–23.2%). HIIT improved exercise capacity
(8.8–59.4%) in patients in SR. Conclusions. Patients in AF or SR undergoing CRT demonstrated distinct
benefits from device implantation and from HIIT as an adjunctive therapeutic strategy. This suggests
that both mainstay and adjunctive therapeutics may need to be managed differently in patients in AF
and SR.
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Cardiac resynchronization therapy (CRT) leads to improve-
ments in exercise capacity, functional class, peak oxygen
consumption (VO2), hemodynamic measures, health-related
quality of life [1] and mortality [2]. However, observational
and intervention studies suggest that the benefits in clinical
or surrogate outcomes of CRT are reduced among patients
with a history of atrial fibrillation (AF) [3–5]. AF precludes
atrioventricular optimization of CRT and may decrease car-
diac output [6]. During AF, atrioventricular synchrony, one
of the main benefits of the CRT, is lost [7]. Importantly,
randomized, controlled clinical outcome trials of CRT have
almost always excluded patients in AF. This is disconcerting
as the prevalence of AF in patients with heart failure is
high and these patients have reduced survival and more
advanced symptoms of heart failure [8].
Exercise training leads to further improvements in func-
tional capacity, hemodynamic measures, and health-related
quality of life in addition to the improvements seen follow-
ing CRT [9,10]. However, this is not an universal finding.
Our group has shown recently that 6 months of HIIT in
patients in CRT did not further improve indices of func-
tional capacity, health-related quality of life, and left ven-
tricular structure and function, compared to CRT alone
[11]. HIIT led to further improvements in exercise perform-
ance, but it remains unclear whether patients with and with-
out regular, organized atrial activity derive the same benefits
from HIIT, as it is known that atrioventricular timing may
influence the response to CRT [3,5]. Here, we report the
results of a post hoc analysis of the previous randomized
control trial [11], with a focus on whether patients in AF
enrolled in HIIT also improve primary predictors of mortal-
ity and morbidity [12] as well as other predictors of rela-
tively poor outcome [13] in chronic heart failure. Thus, the
aim of this post hoc analysis was to evaluate the effects of a
6-month HIIT program on selected estimates of (1) func-
tional capacity and health-related quality of life, (2) multiple
blood biomarkers, (3) echocardiographic parameters, and
(4) exercise performance, in patients stratified by the pres-
ence of AF with the intention of answering the following
questions: (1) Does CRT provide similar benefits in patients
in AF and SR?; and (2) Does HIIT optimize benefits in
patients in AF and SR?
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This is a post hoc analysis of a single-center, randomized
controlled trial aimed at determining the effects of a 6-month
HIIT program initiated soon after CRT implantation (2–4
weeks) on selected noninvasive estimates of systolic function,
exercise performance, the severity of symptoms and health-
related quality of life (Clinicaltrials.gov: NCT02413151). One-
hundred twenty-one patients with chronic heart failure and
referred to CRT at Hospital Santa Marta were eligible for the
trial. The inclusion criteria were: patients classified in NYHA
functional class II-IV; receiving optimal medical therapy for
chronic heart failure, with a stable condition for more than 1
month; reduced ejection fraction, and QRS duration
120ms. Exclusion criteria were: geographical long-distance
address with difficulty/impossibility to attend the hospital-
based HIIT program, incapacitating orthopedic, neurologic or
other limitations that unable the patient to exercise, not
acceptance to participate in the study, inability to sign
informed consent, previous treatment with an intravenous
inotropic agent within the 30 days prior to implantation or
unstable angina pectoris.
Patients were randomized and stratified (by gender, age
and etiology) following CRT. The randomization code was
developed with a computer random-number generator to
select random permuted blocks. Fifty-eight patients were
not randomized either because they declined to participate
in the study or as a result of clinical changes during the
CRT implantation. The remaining 63 patients with moder-
ate to severe CHF (NYHA class II-IV who were under
optimal medical therapy with QRS >120 msec) were
randomized to HIIT (HIIT, n¼ 34) or to the usual care
group (CON, n¼ 29) who were not given specific advice
on exercise training nor underwent supervised training.
No change in cardiac medication occurred as part of the
study protocol.
One patient from the HIIT group died during the study
and 20 patients successfully completed the exercise protocol
with attendance at >80% of the 48 sessions and attended
100% of the evaluation visits. Three of the 29 control
patients died during the study and 9 did not complete
assessments. Therefore, 37 patients (HIIT, n¼ 20; CON,
n¼ 17) completed the study. These 37 patients undergoing
CRT with complete data on functional capacity and health-
related quality of life, B-type natriuretic peptides (BNP), C-
reactive protein (CRP), creatinine and inflammatory cyto-
kines, echocardiographic parameters, and exercise perform-
ance, were stratified by the presence of AF for the sole
purpose of this rhythm post hoc analysis [HIIT (AF ¼ 7; SR
¼ 11); CON (AF ¼ 9; SR ¼ 10; 67.6 ± 1.9 years). All
patients in AF had persistent AF (3 months). All measure-
ments were performed prior to CRT implantation and
repeated 6 months following implantation. No change in
cardiac medication occurred as part of the study protocol.
Optimal medical therapy for chronic heart failure was
considered to include a diuretic, an angiotensin-converting
enzyme inhibitor or an angiotensin receptor blocker and a
beta-blocker, as recommended [14].
The trial was performed according to the Helsinki dec-
laration, approved by the hospital medical ethics research
committee. Written informed consent was obtained from
all patients.
Cardiopulmonary exercise testing
A symptom-limited incremental cardiopulmonary exercise
test (CPET), was performed on a treadmill (Bruce proto-
col) with breath-by-breath gas exchange measurements
(InnocorR, Innovision, Cardiosolutions) and online real-
time calculation of VO2, CO2 production and respiratory
exchange ratio (RER). Subjects were tested at least 2 hours
post-prandial and with their regular medication.
A 12-lead ECG was recorded continuously, and blood
pressure was measured by auscultation using an aneroid
sphygmomanometer (at rest, at the end of each stage and
every min after peak effort).
Subjects were encouraged to exercise until exhaustion, as
defined by the inability to keep up with the treadmill speed,
by leg fatigue or dyspnea, and RER values >1.1) unless clin-
ical criteria for earlier test termination were observed. Peak
VO2 was considered the highest attained VO2 during the
final 30 sec of exercise (10 s average).
Echocardiography parameters
A complete transthoracic echocardiogram was performed
in all patients using a Vivid E9 scanner (GE Healthcare)
with a 3MHz probe, at baseline and at 6-month follow-up
[15,16]. M-mode, two-dimensional, color, pulsed, continu-
ous wave and tissue Doppler data were obtained from
parasternal and apical views, and the standard echocardio-
graphic parameters were calculated. Acquired cine-loop
images with at least 3 cardiac cycles were analyzed offline
(EchoPAC software, GE Healthcare) for additional meas-
ures. Left ventricular ejection fraction (LVEF), and systolic
(LVESV) and diastolic (LVEDV) volumes were determined
from apical 4- and 2-chamber views using Simpson’s
biplane method [17]. The mean of 3 measurements was
considered for analysis. Endocardial borders were manu-
ally traced, and the left ventricular papillary muscles were
included in volume acquisition.
Blood biomarkers analysis
Blood samples were collected through peripheral venous
catheterization into blood collection tubes with anticoagu-
lant (plasma) or without (serum). All laboratory tests were
performed after at least 6 h fasting and at rest in a supine
position in the same laboratory using hospital protocol, and
assays were determined according to the manufacturer’s
recommendations. Concentrations of TNF-a, IL-6 were
determined using commercially available ELISA kits (R&D
Systems, USA), BNP was analyzed from plasma on a
Spinchron DLX 800 (Beckman Coulter) centrifuge using a
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two-step chemiluminescence assay, and CRP was deter-
mined with a nephelometer (Siemens BN ProSpecT). Serum
creatinine levels were measured using the Jaffe method
(Roche Diagnostics GmbH).
Health-related quality of life
Patient health-related quality of life was assessed using a
validated Portuguese version of the HeartQoL, a 14-item
self-administered questionnaire enabling respondents to
recall how much their heart problem bothered them during
the past four weeks, which has been validated in patients
with chronic heart failure [18]. The HeartQoL is scored on
a four-point Likert scale (0–3) with higher scores represent-
ing better health-related quality of life. A global, physical
and emotional HeartQoL score can be calculated [18].
Exercise training
The HIIT was initiated soon after CRT implantation (2–4
weeks). Sessions were supervised, hospital-based, ECG moni-
tored and implemented twice a week, each for 60min, on
non-consecutive days for 6 months (48 sessions). During the
first month, each interval training and the active pause were
increased by 30 sec on a weekly basis, 4min of work with
3min of active rest were accomplished. Every session
included a 10-min warm-up and a 5–7min cool-down.
Starting from the second month, the HIIT consisted of 4
interval training periods (high intensity: 90–95% of maximal
heart rate if below the device threshold, and if not, 90–95%
of the device threshold was used) with 3 lower-intensity
active periods (moderate intensity: 60–70% of maximal heart
rate if below the device threshold) between interval training
periods [19]. The CON group was given no specific advice
on exercise training and underwent no supervised training.
Statistical analysis
All data are reported as mean ± standard error of the
mean and statistical significance was established a priori
as p< .05. Normality of distribution for variables was
assessed qualitatively using histograms and Q-Q plots as
well as quantitatively using the Shapiro-Wilk test, kurtosis
and skewness summary statistics. When distribution was
found to be skewed, log transformations were performed
to conform to normality. Descriptive characteristics were
compared using ANOVA for continuous variables and
Qui-squared tests for categorical data.
Since this post hoc analysis was intended as an efficacy
analysis, we focused on a per-protocol analyses, which
included the patients in CRT that successfully completed the
exercise protocol with attendance rates superior to 80%.
Differences between groups (HIIT AF, HIIT SR, CON AF
and CON SR) at baseline and postintervention, changes
over time within each group and any interaction effect were
assessed by multiple mixed designed two-way repeated
measures analysis of variance (ANOVA).
The statistical analyses were computed and analyzed
using the SPSS Statistics 22.0 (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of the Patients undergoing CRT by
heart rhythm control are displayed in Table 1.
The effects of 6 months of HIIT following CRT on
Functional Capacity and health-related quality of life, serum
inflammatory response, echocardiographic parameters and
exercise performance, in AF and SR patients are presented
in Table 2 by rhythm groups.
Does CRT provide similar benefits in patients in AF and
SR? [CON AF x CON SR]
No differences were found in NYHA class and health-related
QOL between patients in AF and SR at baseline or postinter-
vention (p> .05). Health-related QOL (82.8–101.1%; p< .001;
g2 ¼ 0.570) improved over time in both groups. However,
a significant interaction effect was found in NYHA class
(23.8–46.0% p< .001; g2 ¼ 0.743; p¼ .034), as improvements
were greater in patients in SR.
TNF-a, BNP, CRP and Creatinine did not differ between
patients in AF and SR at baseline or postintervention but
serum concentrations of IL-6 were superior in AF compared
to SR (p¼ .014). Still, no significant improvements were
observed in serum BNP and inflammatory markers with
device implantation in either group (p> .05).
No differences were found in LVEF, LV Mass, LVEDV
or LVESV between patients in AF and SR at baseline or
postintervention (p> .05). Increases in LVEF (31.1–58.8%;
p¼ .002; g2 ¼ 0.432) were observed with device implant-
ation. LVESV, LVEDV and LV Mass did not change signifi-
cantly with device implantation.
Peak HR, RER and peak VO2 did not differ between
patients in AF and SR at baseline or postintervention and
did no change over time with device implantation in any
group (p> .05). CPET duration was higher in patients
in SR at baseline (p¼ .018) but not at postintervention
(p¼ .232). Still, no significant changes were observed over
time (p¼ .433).
Table 1. Baseline characteristics of the patients undergoing CRT, by heart
rhythm control.
Unit Atrial Fibrillation Sinus Rhythm
Subjects n 16 21
Age Years 69.4 ± 1.8 66.2 ± 3.18
Males % 78.5 75.0
Etiology %
Ischaemic 47.4 29.2




ACE Inhibitors 100 90.5
Diuretics 93.3 85.7
Body Mass Index Kg/m2 28.2 ± 1.2 26.7 ± 1.0
Heart rate bpm 77± 4 79 ± 4
Systolic Blood Pressure mmHg 116.8 ± 5.0 115.3 ± 3.8
Diastolic Blood Pressure mmHg 64.0 ± 2.8 62.7 ± 2.1
Values are means ± SE.
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Does HIIT provide benefits in patients in SR? [CON SR 3
HIIT SR]
No differences were found in NYHA class and health-related
QOL between intervention and control groups of patients in
SR at baseline or postintervention (p> .05). NYHA class
(46.1–49.8%; p< .001; g2 ¼ 0.853) and health-related QOL
(86.1–145.6%; p< .001; g2 ¼ 0.698) improved in both groups.
In patients in SR, TNF-a, BNP, IL-6, CRP and Creatinine
did not differ significantly between groups at baseline or post-
intervention. Decreases in TNF-a (8.5–42.9%; p¼ .028; g2 ¼
0.252) and BNP (15.3–34.6%; p¼ .032; g2 ¼ 0.232) were
observed in both groups, whereas no significant changes were
observed in IL-6 and Creatinine.
No significant differences were found in LVEF, LV Mass,
LVEDV or LVESV between HIIT and CON groups at base-
line or postintervention. Increases in LVEF (50.0–51.5%;
p< .001; g2 ¼ 0.532) and decreases in LV Mass (9.6–26.2%;
p¼ .003; g2 ¼ 0.456) were observed in both groups
(Figure 1(a,b)).
Peak HR, CPET duration, peak VO2 and RER did not
differ significantly between at baseline or postintervention.
Significant increases were observed in CPET duration
(8.8–59.4%; p¼ .014; g2 ¼ 0.325). However, an interaction
effect was found (p¼ .002; g2 ¼ 0.473), showing that CPET
duration only increased in patients in SR enrolled in HIIT
(p< .001) (Figure 2(a,b)).
Table 2. Effects of 6 months of HIIT following CRT by rhythm control.
Atrial Fibrillation Sinus Rhythm
Unit HIIT Control HIIT Control
NYHA
Baseline 3.0 ± 0.6 2.6 ± 0.4 2.8 ± 0.1 2.9 ± 0.1
Post-Intervention 1.2 ± 0.5þD 2.0 ± 0.8þ 1.4 ± 0.2þD 1.6 ± 0.2þ
Quality of Life
Baseline 0.9 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 1.0 ± 0.2
Post-Intervention 1.8 ± 0.3þD 1.7 ± 0.3þ 1.9 ± 0.1þD 1.8 ± 0.2þ
TNF-a pg/mL
Baseline 2.4 ± 0.6 2.3 ± 0.5 3.0 ± 0.5 2.4 ± 0.5
Post-Intervention 2.1 ± 0.6D 2.3 ± 0.5 1.7 ± 0.5D 2.2 ± 0.5
BNP pg/mL
Baseline 583.7 ± 308.9 935.8 ± 338.4 378.1 ± 99.1 404.9 ± 99.1
Post-Intervention 499.5 ± 320.2D 840.4 ± 350.8 320.1 ± 79.4þD 264.9 ± 79.4þ
IL-6 pg/mL
Baseline 11.28 ± 3.74 10.66 ± 3.34 6.43 ± 1.35 3.45 ± 1.11
Post-Intervention 11.85 ± 3.67 6.16 ± 3.28 2.85 ± 1.39 4.61 ± 1.13
Creatinine mg/L
Baseline 1.32 ± 0.17 1.31 ± 0.16 1.07 ± 0.14 0.96 ± 0.15
Post-Intervention 1.16 ± 0.16 1.35 ± 0.15 1.11 ± 0.18 1.09 ± 0.20
CRP mg/L
Baseline 4.10 ± 1.90 3.86 ± 1.77 3.93 ± 1.33 3.14 ± 1.45
Post-Intervention 1.81 ± 0.58 1.98 ± 0.55 1.77 ± 2.03 6.21 ± 2.22
LVEF %
Baseline 27.1 ± 3.0 27.6 ± 2.6 26.7 ± 2.2 24.1 ± 2.4
Post-Intervention 31.9 ± 4.7þ 36.1 ± 4.1þ 40.0 ± 2.9þD 36.5 ± 3.2þD
LV Mass g
Baseline 286.8 ± 50.7 401.8 ± 50.7 376.8 ± 30.9 335.4 ± 36.9
Post-Intervention 285.6 ± 51.3 356.8 ± 51.3 278.2 ± 29.6þD 303.1 ± 35.4þD
LV EDV ml
Baseline 251.8 ± 48.0 242.0 ± 37.9 169.3 ± 32.7 241.8 ± 32.7
Post-Intervention 200.4 ± 44.8 236.4 ± 35.4 191.9 ± 32.7 229.5 ± 32.7
LV ESV ml
Baseline 180.5 ± 37.6 180.0 ± 32.6 114.7 ± 23.7 182.0 ± 23.7
Post-Intervention 152.7 ± 37.9 158.1 ± 32.9 136.7 ± 22.6 147.3 ± 22.6
Peak HR bpm
Baseline 114 ± 10 139 ± 11 125 ± 7 128 ± 7
Post-Intervention 107 ± 10 118 ± 12 125 ± 5 129 ± 5
Peak VO2 ml/kg/min
Baseline 12.6 ± 1.7 12.1 ± 1.7 15.3 ± 2.0 18.7 ± 2.1
Post-Intervention 15.0 ± 2.3þ 15.6 ± 2.3þ 17.5 ± 1.3 18.1 ± 1.3
CPET Duration seg
Baseline 331 ± 91 258 ± 99 418 ± 67 614 ± 75
Post-Intervention 544 ± 92D 403 ± 101 666 ± 54þD 555 ± 61
RER unitless
Baseline 1.10 ± 0.07 0.99 ± 0.07 0.98 ± 0.04 0.99 ± 0.04
Post-Intervention 1.09 ± 0.04 1.00 ± 0.04 1.03 ± 0.02 0.97 ± 0.03
Symbols indicate postintervention values are significantly different from baseline values (p< .05) in: þ HIIT vs Control in patients in SR or AF; D HIIT SR vs HIIT
AF;  Control SR vs Control AF. Values are means ± SEM.
HIIT: High Intensity Interval Training Group; NYHA: New York Heart Association Functional Class; TNF-a: Tumor necrosis factor; BNP: Brain natriuretic pep-
tide; IL-6: Interleukin-6; CPR: C-reactive protein; LVEF: Left Ventricular Ejection Fraction; LV Mass: Left Ventricular Mass; LV EDV: Left Ventricular End-
Diastolic Volume; LV ESV: Left Ventricular End-Systolic Volume; Peak HR: Heart rate at peak effort during cardiopulmonary exercise testing; Peak VO2:
Oxygen consumption at peak effort during cardiopulmonary exercise testing; CPET duration: Cardiopulmonary exercise testing duration; RER: Respiratory
Exchange Ratio.
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Does HIIT provide benefits in patients in AF? [CON AF x
HIIT AF]
Patients in AF enrolled in HIIT had higher NYHA class at
postintervention compared to those in CON (p¼ .032), but
not at baseline (p¼ .245). HRQOL did not differ between
groups at any time point and improved equally in patients in
both groups (101.1–106.3%; p¼ .002; g2 ¼ 0.555). However,
an interaction effect was observed in NYHA class in patients
in AF, so that improvements in functional capacity class
were higher in those enrolled in HIIT (23.9–61.0%; p¼ .004;
g2 ¼ 0.515).
TNF-a, BNP, IL-6, CRP and Creatinine did not differ
significantly among patients in AF at baseline or postinter-
vention and did not improve significantly with time.
No significant differences were found in LVEF, LV Mass,
LVEDV or LVESV among patients in AF at baseline or
postintervention. Increases in LVEF (17.4–31.1%; p¼ .011;
g2 ¼ 0.381) were observed in both groups (Figure 1(a,b)).
LVESV, LVEDV and LV Mass did not change significantly
over time.
Peak HR, CPET duration, peak VO2 and RER did not dif-
fer significantly among patients in AF at baseline or postin-
tervention. Significant increases in peak VO2 were observed
in both groups (19.5–23.2%; p¼ .002; g2 ¼ 0.644; Figure
2(a,b)). Peak HR, CPET duration and RER did not change
significantly over time.
Does HIIT provide similar benefits in patients in AF and
SR? [HIIT AF 3 HIIT SR]
Improvements in NYHA class (50.0–61.1%; p< .001; g2 ¼
0.883) and health-related QOL (106.3–145.6%; p< .001; g2
¼ 0.697) were observed in both exercising groups.
TNF-a, BNP, IL-6 CRP and Creatinine did not differ sig-
nificantly between patients in AF and SR enrolled in HIIT
at baseline or postintervention. HIIT decreased TNF-a
(11.6–42.9%; p¼ .02; g2 ¼ 0.400) and BNP (14.4–15.3%;
p¼ .03; g2 ¼ 0.294) in both groups, whereas no significant
changes were observed in IL-6, CRP and Creatinine.
No significant differences were found in LVEF, LV
Mass, LVEDV or LVESV between patients in AF or SR
enrolled in HIIT at baseline or postintervention. However,
a significant interaction effect was observed (p¼ .038), sug-
gesting that LVEF increased (50.0%; p< .001; g2 ¼ 0.542)
and LV Mass decreased (26.2%; p¼ .006; g2 ¼ 0.459) only
Figure 1. Effects of 6 months of HIIT following CRT (differences) in (a) LVEF
and (b) LV Mass by rhythm control.  indicates post-intervention value is signifi-
cantly different from baseline (p < .05); Values are means ± SEM. LVEF: Left
Ventricular Ejection Fraction; LV Mass: Left Ventricular Mass.
Figure 2. Effects of 6 months of HIIT following CRT (differences) in (a) peak
VO2 and (b) CPET duration, by rhythm control.  indicates post-intervention
value is significantly different from baseline (p < .05); Values are means ± SEM.
Peak VO2: Oxygen consumption at peak effort during cardiopulmonary exercise
testing; CPET duration: Cardiopulmonary exercise testing duration.
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in patients in SR. LVESV and LVEDV did not change sig-
nificantly with HIIT.
Peak HR, CPET duration and RER did not differ signifi-
cantly between patients in AF and SR enrolled in HIIT at
baseline or postintervention. However, patients in AF had
lower peak VO2 (2.50mL.kg
1.min1) compared to patients
in SR at postintervention (p¼ .041). Increases in CPET dur-
ation (32.0–59.4%; p¼ .007; g2 ¼ 0.0421) were observed in
both groups.
Discussion
Despite the advancement in medicine, management of atrial
fibrillation in patients with chronic heart failure remains a
challenge to healthcare providers. This is reflected by the
relatively higher rate of readmissions along with increased
mortality and morbidity associated with AF [20]. In the pre-
sent analysis, we evaluated the effects of a 6-month HIIT
program on primary predictors of mortality and morbidity
as well as other predictors of relatively poor outcome in
patients in CRT stratified by the presence of AF. The main
findings were that: 1) patients in AF benefitted to a lesser
degree from CRT in functional status than patients in SR.
However, HIIT induced superior improvements in patients
in AF compared to CON; 2) decreases in TNF-a, BNP, and
left ventricular mass were only observed in patients in SR,
whereas increases in peak oxygen uptake were only observed
in patients in AF; 3) HIIT improved exercise capacity in
patients in SR. We consider that these findings outline that
both mainstay and adjunctive therapeutics may need to be
managed differently in patients in AF and SR so as to meet
the goals of the heart failure treatment. However, just as at
present it is not clear whether AF is an independent risk
factor or just a risk marker for increased mortality in
patients with CHF and LV dysfunction, or that converting
AF to SR and preventing the recurrence of AF is superior to
a strategy aimed at preventing tachycardia during AF [21],
we cannot claim that HIIT is an effective strategy to maxi-
mize benefits in patients in AF undergoing CRT.
It has been shown that CRT reduces serum levels of BNP
[22] but our results suggest that heart rhythm may influence
this finding as no changes were observed in patients in AF.
However, interpreting BNP levels in patients with AF
requires special consideration, unlike in patients in SR, as
BNP in AF is the sum of the releases from the ventricle
(reflecting left ventricular function) and the atrium (due to
AF) [23]. Besides, not only chronic AF can affect BNP level,
but also the effect of a paroxysmal AF attack that replaces
SR may simply be reflected in the BNP levels [23]. Although
CRT decreased BNP levels in patients in SR, HIIT did not
add to the benefits of CRT. These findings are consistent
with other studies with patients in AF or SR undergoing
CRT [24,25].
Tolosana et al. showed that the magnitude of functional
improvement and reverse remodeling in patients in per-
manent AF undergoing CRT is similar to that experienced
by patients in SR [26]. However, improvements in LVEF
and LV Mass in our analysis were limited to patients in SR,
and our data suggests that HIIT did not further improve
these benefits. Several studies demonstrate that exercise
training can improve physical fitness [9,10,27,28], vascular
function [29], quality of life [9], and, there is even evidence
of reversing LV remodeling in clinically stable HF patients
[30]. However, the evidence is conflicting as other studies
reported no benefits with exercise training on ventricular
hypertrophy, even with intense training [31,32]. The physio-
logical mechanisms responsible for the remodeling effects of
HIIT remains unknown. They may arise from favorable
improvements, apparently exclusive to patients in SR, in
coronary and peripheral vascular endothelial function [33],
myocardial contractility [34], autonomic balance [35], or
systolic and diastolic wall stress [36]. Subclinical target
organ changes and cardiac remodeling could be the result
of common pathophysiologic pathways [37]. Because large
variation seen in some variables, possibly a function of low
subject numbers, we adopted a conservative approach on
our conclusions due to the risk of type I errors. Even
though the effect sizes were large for most of our findings,
studies with a larger sample size are needed to confirm
these findings.
Patients undergoing CRT demonstrate both central and
peripheral decompensation due to a prolonged inability
to exercise. Therefore, the improvements found in health-
related quality of life and NYHA are important since these
patients are highly symptomatic, in particular patients in AF
who have reduced survival and more advanced symptoms of
heart failure [38]. The association between NYHA functional
classes and poorer outcomes in patients with heart failure
and left ventricular systolic dysfunction is widely recognized
[39]. Consequently, the added benefits provided by HIIT in
patients in AF have likely implications in the risk of hospi-
talization [40] due to reduction in symptoms of fatigue
and dyspnea.
Patwala et al. [9] showed that moderate to vigorous exer-
cise training in addition to CRT was a promising adjunctive
therapeutic leading to further improvements in peak VO2
by improving skeletal muscle performance. However, in the
present analysis we showed smaller increases in CPET dur-
ation and peak VO2 than in that study, and that these ben-
efits were not independent of the heart rhythm control of
the patients. This is important as the study by Patwala et al.
[9] had a smaller percentage of patients with AF than the
present analysis (34% vs 44%). Only a limited number of
studies on exercise training in patients with AF have meas-
ured oxygen consumption and found that peak VO2 and
exercise capacity increased correspondingly [41,42]. Our
findings show that peak VO2 increased in patients in AF
regardless of the allocation group, suggesting that HIIT did
not provide further benefits in patients in AF undergoing
CRT. Future studies should examine whether this finding
might reflect the relatively small number of patients in our
analysis or, differences in frequency, intensity or duration
of the training program applied. Still, increases in peak
VO2 of 20% are noteworthy in these patients and likely
associated with the reported improvements in health-related
quality of life. In the absence of an increase in peak VO2
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at post-intervention in patients in SR, it is possible that
improvements in health-related quality of life in this group
derived from improvements in walking performance and
efficiency factors, contributing to positive effects on the
economy of motion [43] with expectable benefits in the
performance of daily activities.
Limitations
The single-center and post hoc analysis design, the low num-
ber of participants, and the multiple testes performed are
limitations of the present study. However, several strategies
have been used to handle these multiple comparisons: (1) the
eta squared effect size were strong and reported throughout
the manuscript; (2) the conclusions do not advocate for any
treatment decision. Instead, the authors looked for scientific
plausibility and support data from other studies which valid-
ate the present results; (3) the authors focused on global
assessment variables whenever possible such as NYHA func-
tional class, LVEF, LV Mass or peak VO2. Still, this post hoc
analysis was on average underpowered to demonstrate sig-
nificant group differences in (1) functional capacity and
health-related quality of life (1b¼ 0.21 ± 0.07), (2) multiple
blood biomarkers (1b¼ 0.36 ± 0.08), (3) echocardiographic
parameters (1b¼ 0.34 ± 0.01), and (4) exercise perform-
ance (1 b¼ 0.40 ± 0.01).
Determination of several other blood biomarkers at both
time points would have strengthened the discussion of our
analysis. Unfortunately, no such samples were available
from all patients.
Some observations suggest that atrioventricular node
ablation may impact the attainment of maximal benefit
from CRT in patients in AF [44]. Furthermore, exercise
may revert AF to SR in some individuals. The mechanism is
unclear, but possibly involves changes in autonomic tone
affecting the atrium [45]. We do not have follow-up infor-
mation on patients that might have been subjected to atrio-
ventricular node ablation after CRT implantation or might
have reverted to SR. Further studies are needed in patients
who have atrioventricular node ablation and those who
do not.
The ideal dose of exercise training regarding intensity
and duration is still not known in patients undergoing CRT,
with even less information in those with AF. We recognize
that this exercise training program was more intense and
longer than previous studies trying to maximize CRT bene-
fits [9,10], thus our findings add information on the long-
term effect of HIIT in patients in AF.
Conclusion
Patients in AF or SR undergoing CRT demonstrated distinct
benefits from device implantation and from HIIT as an
adjunctive therapeutic strategy. This suggests that both
mainstay and adjunctive therapeutics may need to be man-
aged differently in patients in AF and SR so as to meet the
goals of the heart failure treatment.
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